Galectin Therapeutics (NASDAQ:GALT) Insider Sells $22,850.00 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 4,570 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $5.00, for a total value of $22,850.00. Following the transaction, the insider owned 2,037 shares in the company, valued at approximately $10,185. This represents a 69.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Khurram Jamil also recently made the following trade(s):

• On Monday, June 29th, Khurram Jamil sold 47,467 shares of Galectin Therapeutics stock. The stock was sold at an average price of $5.04, for a total value of $239,233.68.
• On Tuesday, June 23rd, Khurram Jamil sold 7,557 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.14, for a total value of $23,728.98.
• On Tuesday, May 26th, Khurram Jamil sold 568 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.10, for a total value of $1,760.80.

Galectin Therapeutics Stock Up 4.2%

Shares of NASDAQ:GALT opened at $4.51 on Friday. The company has a 50 day moving average of $2.73 and a two-hundred day moving average of $3.03. Galectin Therapeutics Inc. has a 52-week low of $2.03 and a 52-week high of $7.13. The company has a market capitalization of $297.03 million, a price-to-earnings ratio of -11.00 and a beta of 0.35.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). On average, equities analysts anticipate that Galectin Therapeutics Inc. will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On Galectin Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Galectin Therapeutics by 2.9% during the third quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company’s stock valued at $9,520,000 after buying an additional 63,419 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Galectin Therapeutics in the 2nd quarter valued at approximately $1,580,000. Marshall Wace LLP increased its holdings in shares of Galectin Therapeutics by 8.6% in the 4th quarter. Marshall Wace LLP now owns 602,134 shares of the company’s stock valued at $2,505,000 after acquiring an additional 47,873 shares during the last quarter. Wealthspire Advisors LLC lifted its stake in Galectin Therapeutics by 25.5% during the fourth quarter. Wealthspire Advisors LLC now owns 601,973 shares of the company’s stock worth $2,504,000 after purchasing an additional 122,455 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in Galectin Therapeutics by 13.3% in the fourth quarter. Commonwealth Equity Services LLC now owns 334,096 shares of the company’s stock worth $1,390,000 after purchasing an additional 39,195 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research note on Tuesday, June 23rd. Wall Street Zen upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings raised shares of Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Galectin Therapeutics presently has an average rating of “Hold” and a consensus price target of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.